Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Upgraded at Zacks Research

Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Thursday, Zacks reports.

BIOVF has been the subject of several other reports. Pareto Securities upgraded shares of Swedish Orphan Biovitrum from a “hold” rating to a “buy” rating in a research report on Tuesday, October 27th. HC Wainwright reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Wednesday, October 28th. Finally, Nordea Equity Research downgraded Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

View Our Latest Research Report on Swedish Orphan Biovitrum

Swedish Orphan Biovitrum Stock Performance

BIOVF opened at $51.05 on Thursday. The firm has a market cap of $18.17 billion, a P/E ratio of 23.42 and a beta of 0.48. Swedish Orphan Biovitrum has a 52-week low of $35.25 and a 52-week high of $51.05. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88. The business’s fifty day moving average is $46.40 and its 200-day moving average is $45.13.

Swedish Orphan Biovitrum Company Profile

(Get Free Report)

Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.

Recommended Stories

Analyst Recommendations for Swedish Orphan Biovitrum (OTCMKTS:BIOVF)

Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.